Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Vinorelbine in Recurrent/Metastatic TNBC
NCT03932526Phase 2Unknown
- Sponsor
- Liaoning Medical Center
- Start
- Jun 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Vinorelbine + Placebo with Vinorelbine + Apatinib (2 arms). Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03932526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03932526.